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In Brief
Neuronal or synaptic activity has been
implicated in the pathogenesis of
Alzheimer disease. Yamamoto et al. show
that chronic activation of the
hippocampal perforant pathway in APP
transgenic mice, using optogenetics,
augments Ab pathology within the
presynaptic projection area in the dentate
gyrus of the hippocampus.
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In vivo experimental evidence indicates that acute
neuronal activation increases Ab release from
presynaptic terminals, whereas long-term effects
of chronic synaptic activation on Ab pathology
remain unclear. To address this issue, we adopted
optogenetics and transduced stabilized step-func-
tion opsin, a channelrhodopsin engineered to elicit
a long-lasting neuronal hyperexcitability, into the
hippocampal perforant pathway of APP transgenic
mice. In vivomicrodialysis revealed a24% increase
in the hippocampal interstitial fluid Ab42 levels imme-
diately after acute light activation. Five months of
chronic optogenetic stimulation increased Ab
burden specifically in the projection area of the perfo-
rant pathway (i.e., outer molecular layer of the
dentate gyrus) of the stimulated side by 2.5-fold
comparedwith that in the contralateral side. Epileptic
seizures were observed during the course of chronic
stimulation, which might have partly contributed to
the Ab pathology. These findings implicate functional
abnormalities of specific neuronal circuitry in Ab
pathology and Alzheimer disease.
INTRODUCTION
Aggregation of amyloid b peptides (Ab) as senile plaques and
vascular amyloid is the hallmark pathological change in the
brains of patients with Alzheimer disease (AD) (Selkoe et al.,
2012). Recent studies using electrical or pharmacological stimu-
lations have shown that Ab is secreted from neurons in an activ-
ity-dependent manner (Kamenetz et al., 2003; Cirrito et al., 2005,
2008). Furthermore, recent human and animal studies using
molecular and functional imaging techniques have shown that
cortical regions that are most prone to amyloid deposition in
aging or AD, as revealed by amyloid positron emission tomogra-phy (PET) imaging, correspond to those consisting of a func-
tional network termed default mode network, where basal brain
activities at resting state are constantly high (Buckner et al.,
2005; Bero et al., 2012). These observations led to an intriguing
hypothesis that chronic synaptic hyperactivity is causally related
to the deposition of Ab and linked to the pathogenesis of AD.
However, verification of this hypothesis in animal models has
not been feasible due to the limitation in methodologies appli-
cable to long-term repetitive experimentations.
Recently, optogenetics has emerged as a revolutionary
method that enables the selective control of the activities of a
specific population of neurons that are engineered to express
channelrhodopsin (CR) (Yizhar et al., 2011). Optogenetics by
expressing CR has brought about a groundbreaking advance
in the functional analysis of the brain circuitry, including those
involved in brain disorders (Tye and Deisseroth, 2012). However,
classical CRs, like electrical or pharmacological stimulations, are
relatively short acting and have not been suitable for chronic
experiments to model neurodegenerative disorders that require
long-lasting stimulation for months.
In this study, we adopted the recently developed stabilized
step-function opsin (SSFO), taking advantage of its unusual ca-
pacity to keep neurons closer to action potential threshold and
increasing the probability of spiking to endogenous synaptic
inputs as long as for 30 min by a single light stimulation (Yizhar
et al., 2011). We demonstrated that chronic activation of a spe-
cific neuronal tract augments Ab pathology within its presynaptic
projection area in vivo.
RESULTS
Viral Transduction of SSFO and Optogenetic Activation
of Perforant Pathway Neurons in APP Transgenic Mice
To selectively stimulate the cortical projection neurons in the
lateral entorhinal cortex (LEC) that project to the hippocampal
dentate gyrus (DG) through the perforant pathway,weunilaterally
transduced SSFO-enhanced yellow fluorescent protein (EYFP)
or EYFP in adeno-associated virus (AAV) vector driven by a
CaM kinase II a promoter into the LEC of amyloid b precursorCell Reports 11, 859–865, May 12, 2015 ª2015 The Authors 859
Figure 1. Optogenetic Stimulation Activated Perforant Pathway
Neurons
(A) Schematic structures of SSFO-EYFP (SSFO) and EYFP (EYFP) driven under
the control of CaMKIIa promoter in an AAV vector are shown. ITR, the inverted
terminal repeat sequences; CaMKIIa, Ca2+/calmodulin-dependent protein ki-
nase II alpha (promoter); WPRE, woodchuck hepatitis virus posttranscriptional
regulatory element; pA, polyadenylation signal.
(B–I) Immunofluorescence labeling for c-Fos (neuronal activation marker, red)
and YFP (virus expression marker, green) of the coronal sections of mice
infected with AAV-SSFO (B–E) or AAV-EYFP (F–I). Expression of SSFO or
EYFP (green) was observed in perforant pathway neurons of the ipsilateral side
of infection, i.e., LEC (ipsi-LEC, C andG) andOML of the DG (ipsi-DG, B and F),
but not in those of the contralateral side (contra-DG, D and H, and contra-LEC,
E and I). Unilateral optogenetic stimulation increased the levels of c-Fos at
ipsilateral DG (B) and LEC (C) (red), specifically in the SSFO-infected mice.
Note that non-stimulated LEC neurons show modest levels of basal c-Fos
activities (E, G, and I).
Figure 2. Acute Optogenetic Stimulation of the LEC Increased Ab42
Levels in the Hippocampus
(A) Average levels of ISF Ab42 in the hippocampus of APP Tg mice infected
with SSFO detected by an in vivo microdialysis technique. Light stimulation
(13/min for 4 hr) increased the ISF level of Ab42. Mean relative levels of ISF
Ab42 ± SEM (mean of those 1, 2, and 3 hr prior to stimulation as 100%) are
indicated (n = 5).
(B) Quantitative analysis of ISF Ab42 levels at 1 hr of stimulation. ISF level of
Ab42 in the hippocampus of SSFO-infected APP Tg mice was significantly
higher than that for mice infected with EYFP (n = 4 [EYFP] and 5 [SSFO],
respectively; Student’s t test, mean ± SD, *p < 0.05).protein (APP) Tg mice (A7 line; Yamada et al., 2009; Figure 1A).
We also immunostained the brain sections for c-Fos as a marker
of neuronal activation. After 1month of viral infection, we inserted
a fiber optic cannula and stimulated infected neurons of the LEC
by blue light.
Immunofluorescence labeling of the coronal sections of mice
infected with AAV-SSFO-EYFP in the LEC showed protein
expression of SSFO fused to EYFP in the outer molecular layer
(OML) of the DG (Figure 1B), as well as within the LEC around
the injection site (Figures 1C and S1A, low-power view). Ninety
minutes after a single optogenetic activation of LEC neurons
transduced with SSFO-EYFP, ipsilateral LEC neurons exhibited
stronger c-Fos immunoreactivity compared to neurons of the
contralateral side (Figures 1C and 1E), with both being stronger
than prior to light stimulation (data not shown). Neurons in the
ipsilateral DG became c-Fos positive after light stimulation of
the LEC, whereas contralateral DG neurons remained almost
negative (Figures 1B and 1D). In mice infected with AAV-EYFP
in the LEC, LEC neurons of virus-infected or from the contralat-
eral side exhibited moderate c-Fos immunoreactivity at compa-
rable levels (Figures 1G and 1I), and DG neurons were negative860 Cell Reports 11, 859–865, May 12, 2015 ª2015 The Authorsfor c-Fos on both sides (Figures 1F, 1H, and S1B, low-power
view). These results indicate that SSFO-EYFP is optimally trans-
duced to the perforant pathway neurons, which can be activated
by light stimulation of the LEC.
Acute Optogenetic Stimulation of the LEC Increased ISF
Ab42 Levels in the Hippocampus
To determine whether the acute optogenetic stimulation of the
perforant pathway upregulates Ab release in vivo, we transduced
SSFO-EYFP or EYFP into the LEC neurons of A7 mice and
quantitated Ab42 levels in the interstitial fluid (ISF) of the hippo-
campus usingmicrodialysis. We perfused artificial cerebrospinal
fluid (aCSF) containing 0.15% BSA and collected ISF through a
microdialysis probe with 35-kDa molecular weight cutoff mem-
brane inserted into the hippocampus.
We intermittently stimulated LEC neurons of A7 mice infected
with SSFO-EYFP or EYFP for 2 s per minute for 240 min. During
the initial 60 min of stimulation, light stimulation of A7 mice
infected with SSFO-EYFP significantly increased hippocampal
ISF Ab42 levels by 24.3% compared to the average levels 0 to
240 min prior to stimulation, suggesting that optogenetic stimu-
lation effectively enhanced Ab release in vivo (Figures 2A and
2B). During the subsequent stimulation (from 60 to 240 min),
ISF Ab42 leveled off and gradually decreased with increased
variations in Ab levels among animals. No significant increase
in the levels of hippocampal ISF Ab42 was detected with light
stimulation of EYFP-infected A7 mice (Figure 2B).
Effects of Chronic Optogenetic Stimulation of LEC
Neurons on Ab Deposition in the Projection Area of the
Hippocampal Perforant Pathway
We then examined whether chronic optogenetic stimulation af-
fects Ab pathology in the brains of female A7 mice. We carefully
examined Ab pathology throughout the brains, especially in the
OML of the DG, where small, diffuse Ab deposits often form
band-like clusters in a variety of APP transgenic mice (Games
et al., 1995; Mucke et al., 2000). Since SSFO renders infected
Figure 3. Chronic Optogenetic Stimulation of LEC Neurons Increased Ab Deposition at the OML of the DG of Ipsilateral Hippocampus
(A) Schematic representation of the experimental timeline. Virus infection was performed at 9.5 months; light stimulation was started at 10.5 months; and
immunohistochemical (IHC) analysis was done after 1, 3, or 5 months of light stimulation.
(B) The c-Fos immunoreactivity of the hippocampal DG ipsilateral (left) or contralateral (right) to the light-stimulated side in APP Tgmice stimulated for 5months is
shown.
(C) Ab depositions in the DG of hippocampus ipsilateral (left) or contralateral (right) to the side of optogenetic stimulation of the LEC for 5 months in APP Tg mice
infected with SSFO are shown. Scale bar, 200 mm.
(D) Quantitative analysis shows amyloid burden at the OML of the DG ipsilateral (ipsi) or contralateral (contra) to the side of optogenetic stimulation of the LEC for
5 months in SSFO- or EYFP-infected APP Tg mice.
(E) The ratio of amyloid burden at the ipsilateral/contralateral LEC in SSFO- (left) or EYFP- (right) infected APP Tg mice optogenetically stimulated for 5 months
(n = 9 [SSFO] and 10 [EYFP], respectively, in D and E; Student’s t test, mean ± SD, p > 0.05; n.s., no significant differences).neurons hyperexcitable for >30min upon a single 2-s stimulation
(Yizhar et al., 2011), we chose a protocol to chronically stimulate
the LEC of A7 mice once for 2 s every 24 hr, to periodically in-
crease ISF Ab42 levels every day, starting at 10.5 months old
for 1, 3, and 5 months (Figure 3A).Immunohistochemistry for c-Fos showed that neurons in the
DG of both sides were positive at 1, 3, and 5 months, suggesting
that chronic stimulation upregulated expression of immediate
early genes on both hemispheres (Figures 3B, S1D, and S1E),
whereas no change was observed in EYFP-infected miceCell Reports 11, 859–865, May 12, 2015 ª2015 The Authors 861
Figure 4. Chronic Optogenetic Stimulation
of LEC Neurons, Starting at 5.5 Months
Old for 5 Months, Did Not Increase Ab
Deposition
(A) Schematic representation of the experi-
mental timeline. Virus infection was performed at
4.5months, light stimulation started at 5.5months,
and IHC analysis was done after 5 months of light
stimulation.
(B and C) Ab deposition in the DG of hippocampus
ipsilateral (B1 and C1) or contralateral (B2 and C2)
to the side of optogenetic stimulation of the LEC
for 5 months in APP Tg mice infected with SSFO
(B) or EYFP (C). Scale bar, 200 mm.
(D) Quantitative analysis shows amyloid burden at
the OML of the DG ipsilateral (ipsi) or contralateral
(contra) to the side of optogenetic stimulation of
the LEC in SSFO- or EYFP-infected APP Tg mice
(n = 4 [SSFO] or 5 [EYFP], respectively; Student’s
t test, mean ± SD, p > 0.05; n.s., no significant
differences).(Figure S1C). We assessed Ab deposition by immunohistochem-
istry and quantitated the percentage of areas covered by Ab
immunoreactivity (Ab burden) within the OML of the DG by
morphometry (Iwatsubo et al., 1994). We also confirmed that
all animals expressed detectable levels of SSFO-EYFP or
EYFP throughout the perforant pathway by immunohistochem-
istry for EYFP (Figures S1F and S1G).
APP Tgmice transduced either with AAV-EYFP or AAV-SSFO-
EYFP, after 1 month of light stimulation, showed occasional Ab
deposits in the cerebral cortices or hippocampus; however, no
differences in histopathology were observed regardless of the
type of transduced proteins or stimulation side (Figure S2A),
and the Ab burden was at negligible levels (Figure S2B). EYFP-
or SSFO-EYFP-infected mice stimulated for 3 months showed862 Cell Reports 11, 859–865, May 12, 2015 ª2015 The Authorsa small amount of Ab deposits in the
OML of the DG as well as in other areas
of cerebral cortices; a single animal
transduced with SSFO-EYFP exhibited a
larger amount of Ab deposits specifically
in the OML of the stimulated side (Fig-
ure S2A), although the mean levels of
amyloid burden were not significantly
different (0.5%–1.4% in each group,
Figure S2C). In mice optogenetically
stimulated for 5 months, we observed a
significant increase in Ab deposits in the
OML of the stimulated side, compared
with that of the contralateral side (Fig-
ure 3C), by 2.5-fold (24% versus
10% as amyloid burden, p = 0.0098,
Figure 3D), whereas amyloid deposition
in other areas of the cerebral cortex,
including those in the LEC, was present
at similar levels on either side (Figure 3E).
Immunohistochemistry for the C termi-
nus of Ab42 also showed the predomi-
nance of Ab deposits in the OML of thestimulated side (10.3% versus 5.9%, p = 0.022) in the 15.5-
month-old mice transduced with SSFO-EYFP (Figures S3B
and S3C). No other apparent pathological changes besides Ab
deposition were observed. Amyloid burden in the OML of mice
transduced with EYFP as a control was similar on both sides
(13%), which was lower than that of the stimulated side of
SSFO-infected mice (Figures 3D and S3A). We also examined
A7 mice at 10.5 months of age optically stimulated for 5 months
starting at 5.5 months of age, but did not observe the emergence
of premature Ab deposition (Figures 4B–4D).
To determine whether chronic neuronal activation upregulates
production of Ab, or alternatively it affects the release of Ab from
the presynaptic terminals, we quantitated the levels of Ab42,
sAPPb, and sAPPa in the ISF recovered from hippocampus by
microdialysis in 7- to 10-month-old A7 mice after chronic stimu-
lation for 3 months. A single optic stimulation in these mice
elicited a significant increase in Ab42 levels (Figures S4A and
S4B), whereas those of sAPPb (Figure S4C) and sAPPa (Figures
S4D and S4E) were not altered.
During the course of chronic optogenetic stimulation, epileptic
seizures, which appeared to be equivalent to perforant pathway
kindling, were observed exclusively and virtually in all SSFO-
transduced mice (Figure S2D). Typically, the seizures started
after 5 s of light stimulation as a clonic-tonic generalized
convulsion, ceasing within 2 min. Some animals only showed
motor arrest after stimulation, which was sometimes followed
by a convulsion. Epileptic seizures were observed exclusively
following optical stimulation, did not recur after recovery from
a seizure, and were never elicited spontaneously independent
of light stimulation. The epileptic phenotype was never observed
in the EYFP-transduced mice.
DISCUSSION
In this study, we adopted optogenetics to the experimental acti-
vation of a specific neuronal pathway in APP transgenic mice as
a model of AD, to examine the causal relationship between
synaptic activation and Ab pathology, and showed the following:
(1) chronic optogenetic activation of the hippocampal perforant
pathway for up to 5 months of stimulation was feasible based
on AAV-mediated transduction and stable protein expression
of SSFO, a long-acting CR; (2) augmentation of Ab pathology,
possibly through the chronic increase in Ab release, was
achieved in the presynaptic projection area using SSFO by opto-
genetics; and (3) our model implicates hyperactivity of a specific
projection pathway in the augmentation of Ab deposition. Our
study provides strong support for the notion that functional
impairment in neural circuits may underlie Ab pathology and
AD pathogenesis, and further opens up the application of opto-
genetics in chronic experiments in animal models of neurode-
generative disorders.
The main merit of optogenetic techniques is in the selective
control of the activity of neurons by a short-term light stimulation,
depending on the functional specificity of the CR, and selectivity
in the neuronal populations expressing CR. Accordingly, appli-
cation of optogenetics in the study of brain disorders has been
limited to acute experiments, e.g., selectively controlling activ-
ities of a specific subset of neurons involved in functional or
behavioral abnormalities in parkinsonism, epilepsy, affective dis-
orders, or addiction, to unravel the neuronal circuits involved in
these disorders (Tye and Deisseroth, 2012). Taking advantage
of the stability in expression for over several months and perfor-
mance of SSFO to induce a continuous hyperexcitable state by a
single light stimulation, we were able to add an application of
optogenetic stimulation to the in vivo modeling of AD pathology
by a chronic stimulation paradigm. This was not possible previ-
ously with the classical electrical or pharmacological stimulation.
It has been shown previously, using acute electrical or phar-
macological stimulation, that Ab is released from the presynaptic
termini into the ISF by an activation-dependent mechanism in
the perforant pathway of APP transgenic mice (Cirrito et al.,
2005, 2008). Conversely, dissection of the perforant path abol-ished Ab deposition in the OML of the DG, implicating the spe-
cific involvement of perforant pathway neurons in the formation
of Ab deposits in its terminal zone (Lazarov et al., 2002). Our
study has demonstrated that Ab pathology can be modified by
a chronic and intermittent neuronal hyperactivation lasting for
5 months in the presynaptic area of the perforant pathway, link-
ing synaptic activity and Ab deposition in vivo. Since aggregation
of Ab is a concentration-dependent process, it would be reason-
able that an increased supply of soluble Ab from the presynaptic
endings, along with alterations in aggregation and degradation,
accelerated the Ab deposition in the terminal zone of the perfo-
rant pathway.
Notably, 5 months of stimulation that started at a young age
(i.e., 5.5 months old) did not advance the initiation of Ab deposi-
tion. Because aggregation of Ab is a seed-induced process (Jar-
rett and Lansbury, 1993), the initial seed formation that triggers
amyloid deposition in APP transgenic mice is dependent on
the aging of brain tissues, not only on the Ab levels in the ISF.
It remains to be determined whether chronic neuronal activation
upregulates production of Ab, or alternatively if it affects only the
release of Ab from the presynaptic terminals. Our present obser-
vations that levels of Ab42, but not those of sAPPa or sAPPb (the
latter being the product of b cleavage, a rate-limiting step for Ab
production), were increased in the ISF upon optic activation after
chronic stimulation (Figure S4), as well as the lack of changes in
immunoreactivities for APP, sAPPb, sAPPa, and BACE1 in tissue
sections of the LEC and DG (data not shown), may support the
view that an increase in Ab release is one of the major mecha-
nisms underlying the activity-dependent Ab increase.
Our results may be relevant to the observation, in humans and
animals, that cortical areas that develop the largest amount of Ab
deposits in aged or AD brains (e.g., posterior cingulate cortex/
precuneus/retrosplenial cortex) also have the highest basal rates
of metabolic and neural activity measured by glucose PET and
functional MRI, which recently was defined as the default
mode network that is activated when a person is not performing
a specific mental task, i.e., in default state (Buckner et al., 2005;
Raichle et al., 2001; Bero et al., 2012). It has been hypothesized
that the high level of neural activity in these cortical areas
throughout life might make them susceptible to Ab deposition
due to the relationship between synaptic activity and Ab.
It is noteworthy that our mice developed stimulation-induced
epileptic seizures during the course of chronic stimulation. This
additional factor, which can be interpreted as perforant pathway
kindling,might have enhanced the activity-dependent Ab release
from the presynaptic terminals of the perforant pathway.
Recently, the involvement of seizures and latent epileptic activ-
ities in the pathogenesis of AD was highlighted (Palop and
Mucke, 2009). It has been documented that surgically removed
cortical tissues from 10% of patients with temporal epilepsy
exhibited the premature emergence of Ab deposits, as early as
in the fourth decade of life (Mackenzie and Miller, 1994).
While we were able to establish a method to achieve chronic
hyperactivation of a specific neuronal pathway using optoge-
netics, the strength of the neuronal activation might have been
more intense compared to those in physiological condition,
although the extent of increase in lactate levels in hippocam-
pal ISF after optogenetic activation was considerably milderCell Reports 11, 859–865, May 12, 2015 ª2015 The Authors 863
(+74% at 30 min after stimulation) (Figure S4F) compared with
that upon hyperactivation induced by picrotoxin (+342%)
(Yamada et al., 2014). It would be ideal if we were able to control
the activity of SSFO-infected neurons atmoremodest levels for a
longer period. This may enable us to determine whether
increased synaptic activity at physiological levels, such as
occurs in chronically activated neural networks, might also
modify Ab pathology as well as subsequent failures in the
network activities.
EXPERIMENTAL PROCEDURES
Animals
Transgenic mice (line A7) that overexpress human APP695 harboring K670N,
M671L (Swedish), and T714I (Austrian) familial AD mutations in neurons under
the control of Thy1.2 promoter were used (Yamada et al., 2009). C57BL/6J
mice were purchased from Charles River Laboratories. All animals were main-
tained on food and water with a 12-hr light-dark cycle. All experiments were
approved by the Institutional Animal Care and Use Committee of the Graduate
Schol of Medicine at the University of Tokyo.
Construction of AAV Vectors and Transfer to Mouse Brains
AAV was produced in a baculovirus/sf9 system. In brief, a DNA fragment
encoding SSFO-EYFP was ligated to CaMKIIa promoter and inserted into an
AAV vector for amplification in baculovirus. The resultant vector was trans-
formed into DH10BAC and the expression cassette was transposed into bac-
mid and transfected into Sf9 cells to produce baculovirus. The resultant bacu-
loviruswas co-infectedwith anAAV1-packaging baculovirus intoSf9 cells at an
MOI of two. AAVwaspurifiedonAVBsepharose (GEHealthcare). TheAAV frac-
tion was concentrated by ultrafiltration using Amicon Ultra 100K-15 (Millipore).
Then, 1.0 ml AAV solution (1012–1013 genome copies/ml) was stereotaxically
injected into mouse brains through a glass capillary (100-mm tip diameter)
inserted into the LEC. More details on our methods are included in the Supple-
mental Experimental Procedures.
Optical Stimulation
After 4 weeks of AAV infection, mice were again stereotaxically inserted with a
fiber optic cannula into the LEC. In chronic optical stimulation experiments,
female A7 mice (9.5 months old) were infected with AAV coding for SSFO-
EYFP or EYFP, and, after 1month of incubation, micewere optically stimulated
for 2 s every 24 hr (starting at the age of 10.5 months) for 1, 3, or 5 months by
blue light (473 nm, 4 mW). In each group, 6–8 mice were stimulated for 1 or
3 months and 10 mice were used for a 5-month optic stimulation. In acute
stimulation experiments, optic stimulation for 2 s (at 4 mW) was performed
each minute for 4 hr, starting after 6 hr of ISF sampling by microdialysis.
More details on our methods are included in the Supplemental Experimental
Procedures.
In Vivo Microdialysis Combined with Acute Optical Stimulation and
ELISA Quantitation of Ab
A microdialysis cannula was inserted stereotaxically into the hippocampal
area, filled with aCSF containing 0.15% BSA, and set with a dialysis probe
of molecular weight cutoff at 35 or 1,000 kDa. The aCSF was circulated
at the rate of 1.0 ml/min and sampling was started after 2 hr, with mice in a
free-moving state. After recovery of brain ISFs, an equal volume of 1M guani-
dine hydrochloride was added and incubated for 30 min to solubilize and
monomerize the recovered Ab. Levels of Ab42 in ISF were quantitated by
Human/Rat b Amyloid (42) ELISA kit (Wako Pure Chemicals Industries) as
described previously (Iwatsubo et al., 1994). More details on our methods
are included in the Supplemental Experimental Procedures.
Immunohistochemistry and Morphometry
Mouse brains perfused with 4% paraformaldehyde (PFA) were cut into 30-mm-
thick cryosections and analyzed by immunofluorescence for expression of
c-Fos and SSFO-EYFP. Immunohistochemical and morphometric analyses864 Cell Reports 11, 859–865, May 12, 2015 ª2015 The Authorsof Ab deposition were performed on paraffin-embedded, 4-mm-thick coronal
sections of mouse brains stained with a mouse monoclonal anti-Ab antibody
82E1 or anti-Ab(38-42). Quantitation of Ab burden was conducted using
ImageJ software. Four to five consecutive sections, 100 mm apart at the level
of the largest section of hippocampus, were examined and the mean level of
Ab burden was calculated for each animal. The outermost one-third of the
molecular layer throughout the entire extent of the DG was examined. More
details on our methods are included in the Supplemental Experimental
Procedures.
Statistical Analyses
Quantitative data were analyzed statistically by Student’s t test or ANOVA
using Prism 6 (GraphPad).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2015.04.017.
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